High materiality8/10
Evolent Announces Second Quarter 2026 Results
Trading thesisImportance 8/10
EVH should trend higher over the next 12–18 months on Oncology go-live and 25%+ 2027 revenue growth.
Signal detail
News insight
Source-backed analysis, the reasoning behind the signal, and its market context.
AI summary
What happened and why it matters
Evolent Health reports Q2 2026 results with raised 2026 revenue guidance and a stronger 2027 outlook, aided by AI-driven operations and growth in oncology services. The company announced a go-live for an Oncology Performance Suite that could add about $300 million in annualized revenue, alongside a Blues-plan expansion. Medicaid headwinds and membership attrition remain key risks to execution.
- Oncology Performance Suite go-live by December 2026; ~1.5M lives across 11 states.
- 2026 revenue guidance raised to $2.6–$2.7B; 2027 Adjusted EBITDA ≥$150M.
- Two additional partnerships add near-term revenue and longer-term upside.
- Medicaid headwinds and client attrition remain macro risks.
Sentiment rationale
Guidance uplift, a sizable oncology deal with deep revenue potential, and a clear path toward deleveraging create a favorable fundamental setup. Near-term catalysts include the December 2026 go-live and the 2027 growth target; however, monitor Medicaid attrition risk as a potential dampener.
Key facts
- 01
Evolent raises 2026 revenue guidance to $2.6–$2.7B and 2027 growth >25%.
- 02
Oncology Performance Suite to go live in 11 states with ~1.5M lives and ~$300M annualized revenue.
- 03
Q2 results: Adjusted EBITDA $28.05M; cash flow improvements and cost discipline highlighted.
- 04
Medicaid headwinds and membership attrition remain macro risks to profitability.
- 05
Two new partnerships drive near-term revenue momentum and 2027 upside.
Earnings
Earnings. The content centers on quarterly results, non-GAAP measures, and updated guidance plus strategic partnerships—typical earnings-event drivers for EVH.
Related signals
More AI-analyzed coverage connected to this story